



Managing Director's presentation

Annual General Meeting 20 November 2024

Michelle Parker

Disclaimer

Introduction

This presentation has been prepared by Clarity Pharmaceuticals Ltd (ACN 143 005 341) (Clarity or the Company) and contains summary information about Clarity and the business conducted by it as at 20 November 2024. The information in this presentation is for general informational purposes only, does not purport to be complete or comprise all information which a shareholder or potential investor may require in order to determine whether to deal in Clarity shares. It should be read in conjunction with the Company's IPO prospectus and other periodic and continuous disclosure announcements lodged with the ASX.

This presentation is not a prospectus, product disclosure statement or other disclosure document for the purposes of Chapter 6D or Part 7.9 of the Corporations Act 2001 (Cth) (Act) or other offer document under Australian law or the law of any other jurisdiction, including the United States.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and the opinions expressed are fair and reasonable, none of Clarity, nor its advisers (Advisers) nor their respective affiliates, related bodies corporate (as defined in the Act) or securityholders and their respective directors, officers, employees, partners, representatives, consultants, agents or advisers (each a Limited Party and together, the Limited Parties) make any representation or warranty to, or takes responsibility for, the content of this presentation, and nothing contained in this document is, or may be relied upon as, a promise or representation, whether as to the past or future. To the maximum extent permitted by law, the Limited Parties disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation.

Forward looking statements

The information contained in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of Clarity's views on future performance or condition. Past performance cannot be relied upon as an indicator of future performance. This presentation contains certain forward-looking statements. The words "forecast", "estimate", "like", "anticipate", "opinion", "believe", "expect", "project", "predict", "intend", "propose", "should", "could", "may" and other similar expressions are intended to identify future earnings, financial position and performance of Clarity. You are cautioned not to place undue reliance on these statements. These forward-looking statements are based on estimates, projections and assumptions made by Clarity about circumstances and events that have not yet taken place. Although due care and attention has been used in the preparation of these statements, such forward-looking statements are based on numerous assumptions regarding Clarity's present and future business strategies and the political, regulatory and economic environment in which Clarity will operate in the future, and are subject to change without notice. Statements about market and industry trends, which are based on interpretations of current market conditions, may not be reasonable, and are not guarantees or predictions of future performance. Actual results from any clinical trial may vary from any result that is anticipated. Under no circumstances will anything in this presentation create an implication that there has been no change in the affairs of the Company since the date of this presentation.

The actual results or performance of Clarity may be materially different from the results or performance expressed or implied by such forward-looking statements.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including any of the Limited Parties). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forwardlooking statement in this presentation will actually occur. Subject to any continuing obligations under applicable law, the Company expressly disclaims any obligation or undertaking to provide any updates or revisions to any forwardlooking statements in this presentation to reflect any change in expectations in relation to any forwardlooking statement or any change in events, conditions or circumstances on which any statement is based.

Not an offer or financial product advice

The information contained in this presentation is for informational purposes only and should not be considered, and does not contain or purport to contain, an offer, invitation, solicitation or recommendation with respect the purchase or sale of any securities in Clarity (Securities) nor does it constitute legal, taxation, financial product or investment advice. The general information in this presentation has been prepared without taking into account the investigations, financial situation or particular needs of any particular person. This presentation does not constitute an advertisement for an offer or proposed offer of Securities. Investors must undertake their own independent investigations, consideration and evaluation. Neither this presentation nor any of its contents will form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in any transaction nor is it intended to be used as the basis for making an investment decision. This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of, any "US person" as defined in Regulation S under the US Securities Act of 1993 (Securities Act).

Clarity recommends that potential investors consult their professional advisors as an investment in Clarity is subject to investment and other known and unknown risks, some of which are beyond the control of Clarity or its directors and therefore any investment is considered to be speculative in nature.

Market and industry data and other information

Certain market and industry data and other information used in this presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither the Company nor its representatives or its advisers have independently verified, or can assure investors as to the accuracy of, any market or industry data or other information provided by third parties or industry or general publications. Photographs and diagrams used in this presentation that do not have descriptions are for illustration only and should not be interpreted to mean that any person shown in them endorses this presentation or its contents or that the assets shown in them are owned by the Company. Diagrams used in this presentation are illustrative only and may not be drawn to scale.

General

Statements made in this presentation are made only as at the date of this presentation. The information in this presentation remains subject to change without notice. The Company may in its absolute discretion, but without being under any obligation to do so, update or supplement this presentation. Any further information will be provided subject to the terms and conditions contained in this Disclaimer.

Key FY24 highlights


CLINICAL & REGULATORY	OPERATIONS
 Actively progressing 7 clinical trials + 1 IIT of Clarity's three key product areas ⁶⁴Cu-SAR-bisPSMA Phase III diagnostic trial ongoing with another Phase III trial commencing shortly Fast-Track Designation for ⁶⁴Cu-SAR-bisPSMA pre-prostatectomy Initial therapy data with ⁶⁷Cu-SAR-bisPSMA is very encouraging 	 NorthStar manufacturing commercial scale Cu-67 and ⁶⁷Cu-SAR-bisPSMA final drug product under one roof for Phase I/II and Phase III trials Nucleus RadioPharma manufacturing ⁶⁷Cu-SAR-bisPSMA drug product for Phase I/II and Phase III trials SpectronRx manufacturing Cu-64 and ⁶⁴Cu-SAR-bisPSMA diagnostic product Supply agreement for Ac-225 with TerraPower
PEOPLE & CULTURE	FINANCIAL
 Grown the team to 62 employees in the U.S. and Australia Approx. 15 promotions in the last year Growing senior executive team & aligning roles of existing team members 	 Strong cash balance of \$123.7 million as at 30 September 2024 Anticipated R&D tax incentive for FY24: ~\$11 million Cash runway to fund existing trial pipeline and provide cash runway to 2026

• Continued strong capital markets for radiopharm



Three core product areas in clinical trials

Clarity has potential to address multiple oncology indications with unmet needs through a range of products and their applications. These include large indications, such as prostate and breast cancers, as well as small and orphan indications, such as neuroendocrine tumours (NETs) and neuroblastoma, an aggressive childhood cancer.



• Combined as a theranostic using ⁶⁴Cu-labelled products to select patients for therapy with ⁶⁷Cu-labelled products

Clinical stage assets in multiple cancers

Clarity's products are progressing through sponsored clinical trials in the U.S. and Australia

Clinical development pipeline as of 20 November 2024

0	Indication	Product	Application	Current Trial	Discovery	Preclinical	Phase I	Phase 2	Phase 3	Current pro
Û	Prostate Cancer	SAR-bisPSMA	Theranostic mCRPC	S E <mark>Cu</mark> R E				*		12 month pro
NS		SAR-bisPSMA	Diagnostic in pre- radical prostatectomy	CLARIFY			*			Note clinical o
		SAR-bisPSMA	Diagnostic in BCR PCa	AMPLIFY						pipeline is indie subject to revie
		SAR-BBN	Diagnostic in BCR PCa	SABRE						All U.S. studie under Investig Applications
0		SAR-BBN	Theranostic mCRPC	С ∗Э М В А Т						
S S	Neuroblastoma	SARTATE	Theranostic	CL04						
Ð	NETs	SARTATE	Diagnostic	DISCÓ			ak.			
	SAR Discovery	Ac-225 bisPSMA	Theranostic		*					
0		TCT and I/O combination	Theranostic		*					
	Platform	Pan-cancer TCT	Theranostic		*					
		Multiple novel TCTs	Theranostic		*					


month progress

ote clinical development peline is indicative only, bject to review.

U.S. studies are conducted der Investigational New Drug plications

SAR-bisPSMA

Targets the Prostate Specific Membrane Antigen (PSMA), present in the majority of prostate cancers



Co-PSMA - Phase II Investigator-Initiated Trial (IIT)

- Led by Prof Louise Emmett at St Vincent's Hospital Sydney
- Evaluates the performance of ⁶⁴Cu-SAR-bisPSMA in • comparison to standard-of-care ⁶⁸Ga-PSMA-11 product for the detection of prostate cancer recurrence
- First patient first visit expected soon ٠

LARITY


SECuRE - Phase I/IIa

- Cohort 4 ongoing 2 therapy cycles (12GBg)
- No DI Ts observed to date ٠
- First 3 participants in Cohort 4 had reductions in prostate-specific ٠ antigen (PSA) levels following 2 doses of 12GBg of ⁶⁷Cu-SARbisPSMA, with the largest drop being 98% to date

CLARIFY - Phase III

- CLARIFY **Registrational Phase III imaging** trial of participants with high-risk prostate cancer prior to radical prostatectomy using ⁶⁴Cu-SAR-bisPSMA
- Fast-Track Designation granted by the U.S. FDA ۰
- Recruitment ongoing ٠

COBRA - Phase I/II



- Positive results released with data used to support the End of Phase meeting with the U.S. FDA
- COBRA abstract selected as a Top-Rated Oral Presentation at EANM ٠ 2024 Congress

AMPLIFY - Phase III

- Registrational Phase III imaging trial with ⁶⁴Cu-SAR-bisPSMA in prostate cancer patients with biochemical recurrence (BCR)
- Recruitment will commence early 2025 ۰



SAR-bisPSMA market


PSMA based diagnostics

- Current U.S. patient pool for PSMA-PET imaging is **~400k** scans per year between initial staging, suspected recurrence and patient selection for targeted therapy
- At US\$5,000 per patient dose this represents a U.S. market potential of **~US\$2Bn**/year
- By 2030 this is expected to grow to **>700k** scans per year, representing a U.S. market potential of **>US\$3Bn/year**
- 2025 CMS reimbursement changes favour the long-term potential of the best-in-class PSMA PET agent



ARITY

Quarterly US Sales (\$M USD) - PSMA PET Diagnostics



estimations

SAR-bisPSMA aims to disrupt current diagnostic and therapeutic utilisation as a best-in-class agent for imaging and treating prostate cancer


PSMA based therapy (mCRPC)

- Current U.S. market opportunity (post chemo): >US\$5Bn
- Future U.S. market opportunity (including pre-chemo): >US\$10Bn
- Pluvicto reached blockbuster status in Q3 2024 with sales exceeding US\$1Bn

Therapy program with ⁶⁷Cu-SAR-bisPSMA

Trial overview


- Phase I/II study in mCRPC
- Participants do not need to have received chemotherapy
- Dose escalation followed by cohort expansion with up to 4 cycles of therapy






Trial highlights to date

- Cohort 3 completed, now progressing the final 3 patients in cohort 4 at 12GBq (Pluvicto dose capped at 7.4GBq)
- First 3 participants in Cohort 4 had reductions in prostate-specific antigen (PSA) levels following 2 doses of 12GBq of ⁶⁷Cu-SAR-bisPSMA, with the largest drop being 98% to date
- No DLTs have been observed to date
- Cohort 4 will be followed by a cohort expansion phase of the trial, pending safety evaluation






PSA reductions shown as the response observed post-single dose of ⁶⁷Cu-SAR-bisPSMA. PSA pre-dose value represents the most recent test result prior to the administration of ⁶⁷Cu-SAR-bisPSMA. At study entry, patients had median PSA of 117.1 ng/ml.




SE

Radiographic partial response and PSA80 following 2 cycles of ⁶⁷Cu-SAR-bisPSMA (12GBq)



PSA reduction following 3 cycles of ⁶⁷Cu-SAR-bisPSMA





mCRPC patient from cohort 4 showing extensive metastasis to the lymph nodes (regions highlighted by the red lines, images on the left). ⁶⁴Cu-SAR-bisPSMA images show reduction in tumour volume from pre- to post-treatment with ⁶⁷Cu-SAR-bisPSMA (2 cycles, 12GBq). rPR: radiographic partial response by RECIST v1.1 assessment. PSA reduction: nadir not reached (from 157.4 to 3.2 ng/mL). Images shown as maximum intensity projections. Data cut-off 15 Nov 2024.

⁶⁷Cu-SAR-bisPSMA has a <u></u>favourable safety profile

Cohorts 1-3 Adverse event (AE)	Grade 3 N = 15 (100%)
Any drug-related AEs	3 (20)
Occurring in at least 1 participant	
Anaemia	2 (13)
Thrombocytopenia	1 (7)
Contraction Leukopenia	1 (7)
Lymphopenia	1 (7)

Demographics summary: all participants had mCRPC at study entry. Median number of lines of therapy prior to receiving ⁶⁷Cu-SAR-bisPSMA: 4 (range 2-6). Previous treatments included ADT, ARPI, investigational agents, chemotherapy (67%, 10/15) and other radioligand therapies. Median PSA at study entry: 117.1 ng/ml (range 0.11-1,494.2).

S E Cu R E


Cohorts 1-3 (single dose): most adverse events (AEs) were lower Grade, with only 3/15 patients developing Grade 3 AEs (no Grade 4/5)

- No AEs were related to ⁶⁴Cu-SAR-bisPSMA
- AEs were reported as related to ⁶⁷Cu-SARbisPSMA in 8 out of the 15 trial participants (all Grades)
- Most AEs related to ⁶⁷Cu-SAR-bisPSMA were Grade 1 or 2
- No Grade 4 or 5 AEs were reported in the study


Cohort 4 (multi-dose): almost all AEs were mild or moderate (majority either resolved or improved at the last assessment). No DLTs observed.



⁶⁷Cu-SAR-bisPSMA adaptive dosing leads to <u>durable PSA</u> <u>response and disease control</u>: EAP case report 1



PSA reduction following multi-doses of ⁶⁷Cu-SAR-bisPSMA




mCRPC patient with metastasis to the bones (blue arrows, images). Definitive radiation therapy in 2013. Previous systemic therapies: ADT, 2 ARPIs. Images show reduction in lesion uptake (⁶⁴Cu-SAR-bisPSMA PET) following 4 doses of ⁶⁷Cu-SAR-bisPSMA (4GBq each), with reduction in PSA of 94.4%. Reduction in SUVmax and tumour volume: 72.5% and 41.6%, respectively. New bone lesions detected in latest PET (red circles, approximately 14 months post-4th dose of ⁶⁷Cu-SAR-bisPSMA). Recent rising in PSA led to the administration of a 5th cycle of ⁶⁷Cu-SAR-bisPSMA (8GBq). PSA reduction of 47.52% vs latest PSA peak (10.1 ng/mL; PSA continues to decline). AE related to ⁶⁷Cu-SAR-bisPSMA: mild (Grade 1) thrombocytopenia (improving). Images: maximum intensity projection. Graph dash lines: administration of ⁶⁷Cu-SAR-bisPSMA. EAP: Expanded Access Program. Data cut-off 28 Sep 2024.

⁶⁷Cu-SAR-bisPSMA adaptive dosing leads to <u>durable **complete**</u> <u>response</u>: EAP case report 2

Tx break:

3 months

Complete anatomical response (CT; RECIST v1.1) Complete molecular response (PET) Complete biochemical response (undetectable PSA)




Images: PET scan showed no uptake of ⁶⁴Cu-SAR-bisPSMA above the background level following 2 doses of ⁶⁷Cu-SAR-bisPSMA, demonstrating a complete molecular response. Dash lines in graph: administration of ⁶⁷Cu-SAR-bisPSMA. Safety: xerostomia (Grade 1), fatigue (Grade 2), both resolved; dysgeusia (Grade 1), improved; thrombocytopenia (Grade 1); anaemia (Grade 3, improved to Grade 2). EAP: Expanded Access Program. PSA limit of detection 0.05 ng/mL. PSA limit of detection: 0.05 ng/ml. Images: maximum intensity projection. Data cut-off 14 Oct 2024.

PSA reduction following 2 cycles of ⁶⁷Cu-SAR-bisPSMA

Diagnostic program with ⁶⁴Cu-SAR-bisPSMA


Trial overview

S



Assessing same-day and next-day imaging of ⁶⁴Cu-SAR-bisPSMA in this patient population

Recruitment is ongoing



Screening

🔎 C L A R I T Y

- ⁶⁴Cu-SAR-bisPSMA administration followed by PET/CT scan
- . "Same day" and "next day" imaging
- I. Surgical removal of the prostate and pelvic lymph nodes
- 5. Laboratory assessments (histopathology) to confirm the results of the PET scan

CLARIFY

U.S. FDA Fast Track Designation (FTD)


- U.S. FDA granted FTD for ⁶⁴Cu-SAR-bisPSMA for PET imaging of PSMA positive prostate cancer lesions with suspected metastasis who are candidates for initial definitive therapy
- FTD is designed to expedite the development and regulatory review of novel drugs addressing serious conditions with significant unmet medical need
- Fast track products must show advantage over available therapy

Key benefits

- Potentially faster product approval review process
- More frequent communication with the FDA
- Rapid query resolution
- Clarity can submit sections as they are completed rather than waiting for complete application package

14

SAR-bisPSMA is safe and effective in detecting tumours in prostate cancer patients




Patients with negative/equivocal SOC scans - COBRA study (biochemical recurrence)

82% more lesions detected on next-day imaging (2 mm-range)

Ø	⁶⁴ Cu-SAR-bisPSMA					
	Same-day imaging	Next-day imaging				
For perso		R				

34% more patients with a positive scan on next-day imaging



CLARITY

USe

Left images. Up to 80 lesions detected on same-day imaging vs. up to 153 lesions on next-day imaging across all participants. Right images: pelvic lymph node detected by ⁶⁴Cu-SAR-bisPSMA on next-day imaging, but not with Pylarify® at screening. Patients with a positive ⁶⁴Cu-SAR-bisPSMA scan: from up to 58% to up to 80%, same and next-day imaging respectively). Nordquist et al., SNMMI 2024.

Higher uptake and contrast in lesions on next-day imaging and detection of lesions in the 2mm range








Figure 1. Pelvic lymph nodes showing uptake of ⁶⁴Cu-SARbisPSMA on next-day imaging (arrows, B and D). Blue arrow: lesion size 3.8 mm x 4.4 mm, SUVmean 20.6, SUVmax 22.1 and TBR 130.1. Green arrow: lesion size also 3.8 mm x 4.4 mm, SUVmean 11.9, SUVmax 12.8 and TBR 75.3. Red arrow: size >5 mm. Inset in top images (A, B) displays pelvic region (bottom images, C and D).

ARITY

SUVmean and SUVmax in lesions detected by ⁶⁴Cu-SAR-bisPSMA



TBR of lesions detected by 64Cu-SAR-bisPSMA




>80% increase in mean SUVmean and SUVmax (same-day vs. next-day imaging)

>5x higher mean TBR
(same-day vs. next-day imaging)

Figure 2. SUVmean/max and TBR comparing same-day (Day 0) and next-day (Day 1) imaging. Average increase across 3 readers. SUVmean: mean standardised uptake value. SUVmax: maximum standardised uptake value. TBR: tumour-to-background ratio. The SUVmax, SUVmean and TBR were assessed in up to 25 lesions per patient on each ⁶⁴Cu-SAR-bisPSMA scan. Ranges across the readers for same-day and next-day imaging, respectively: SUVmean 6.6-9.9 and 14.7-15.8; SUVmax 13.9-14.0 and 22.2-33.4; TBR 23.2-25.4 and 118.1-181.7. TBR = SUVmax of the lesions / SUVmean of the gluteus region.

SAR-Bombesin

Targets the Gastrin Releasing Peptide receptor (GRPr), which is present in a number of cancers, including breast and prostate cancers



Single pelvic lymph node uptake seen on $^{64}\text{Cu-SAR-Bombesin}$ on both Day 1 and Day 2. A subsequent biopsy has confirmed prostate cancer.

CLARITY

COMBAT – Phase I/IIa therapy

C > M B A T

- ⁶⁴Cu-SAR-BBN and ⁶⁷Cu-SAR-BBN for identification and treatment of GRPr-expressing mCRPC in patients who are ineligible for therapy with ¹⁷⁷Lu-PSMA-617
- Progressing through dose escalation across 5 sites in the U.S.
- Presented at ASCO GU (Jan 24) and SNMMI (Jun 24)

SABRE – Phase II

 Phase II PET imaging trial of participants with PSMA-negative BCR of prostate cancer using ⁶⁴Cu-SAR-BBN




- Follow up period completed with data review and analysis ongoing
- Initial data readout anticipated Q1 2025
- Presented at ASCO GU (Jan 24) and SNMMI (Jun 24)

BOP – Phase II

- Investigator Initiated PET imaging trial of participants with negative PSMA PET or low PSMA expression disease in patients with suspected BCR of prostate cancer and patients with mCRPC using ⁶⁴Cu-SAR-BBN led by Prof Louise Emmett at St Vincent's Hospital Sydney
- Manuscript published in the Journal of Nuclear Medicine (Aug 2024)

SARTATE

Targets the Somatostatin Receptor 2 (SSTR2), which is present in an aggressive childhood cancer, neuroblastoma, as well as neuroendocrine tumours (NETs), among other cancers



SARTATE



CL04 – Phase I/IIa

- ⁶⁴Cu/⁶⁷Cu-SARTATE theranostic clinical trial in high-risk neuroblastoma
- Cohort 4 recently completed. Update provided shortly.

DISCO – Phase II

- A diagnostic imaging study of ⁶⁴Cu-SARTATE using PET on patients with known or suspected NETs
- Recruitment closed with final patients soon to complete the follow-up period
- Initial data readout anticipated mid 2025

Scaling manufacturing for commercial launch

Clarity continues to strengthen and expand its manufacturing and supply chain footprint, creating additional capacity and flexibility to supply products to any state in the U.S. for upcoming and ongoing late-stage clinical trials



Clinical Supply Agreement for ⁶⁷Cu-SAR-bisPSMA

Large-scale manufacturing of copper-67 isotope and cGMP ⁶⁷Cu-SAR-bisPSMA drug product in the U.S. under one roof Nucleus RadioPharma

Drug manufacturing of ⁶⁷Cu-SAR-bisPSMA

Manufacturing the ⁶⁷Cu-SAR-bisPSMA drug product at Nucelus RadioPharma's state-of-the-art facility in Rochester, MN



Supply Agreement for the production of Cu-64

The first private supplier of Cu-64 to join Clarity's network in the U.S., which will support the Company as it progresses towards commercial launch



Actinium-225 program

Supply of therapeutic alphaemitting actinium-225 for Clarity's Targeted Alphaparticle Therapy (TAT) program with bisPSMA



Highly experienced team





Robert Vickery Company Secretary





Michelle Parker CEO



Dr Othon Gervasio Chief Medical Officer



Kathryn Williams-Day VP - Regulatory Affairs and Quality



Dr Colin Biggin COO



Dr Matt Harris Chief Technology Officer



David Green Chief Financial Officer



Eva Lengyelova EVP – Clinical Development



Mary Bennett Head of People and Culture



Clarity's management team has a diverse and in-depth level of expertise spanning corporate finance, management, clinical, operations, commercialisation and industry

- Development, approval and launch of 1st approved radiopharmaceutical therapy product for prostate cancer (Xofigo)
- Decades of experience spanning across science, nuclear medicine/PET and pharmaceutical industries
- Investment banking experience focused on the life sciences sector

S Thank you

Contact details

Dr Alan Taylor Executive Chairperson E: alan.taylor@claritypharm.com

Michelle Parker

Managing Director E: Michelle.Parker@claritypharmaceuticals.com